EPI-326 for Advanced Head and Neck or Lung Cancer
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 110 (estimated)
- Sponsor
- EpiBiologics · Industry
This trial is looking for patients with advanced head and neck cancer or lung cancer caused by an EGFR mutation. Participants will receive doses of EPI-326 to help determine its safety and effects on their cancer.
You may be able to join if
- I have a life expectancy of more than 12 weeks.
- I have a performance status of 0-2.
- I have been diagnosed with lung cancer or head and neck cancer.
- My lung cancer has an EGFR mutation.
- I have locally advanced or metastatic lung cancer or head and neck cancer.
- I have adequate organ function.
You may not be able to join if
- I have a history of uncontrolled illness.
- I have symptomatic brain metastases.
- I have been diagnosed with another cancer in the past 3 years, except if it was treated completely and there is no active disease.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityA phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.
Loading trial locations…